EUVIMEDEUVIMED entdecken
Open Access

Evaluation of [ 89 Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer

Maxwell Ducharme iD, Lucinda Hall iD, Whitney Eckenroad, Shelbie J Cingoranelli, Hailey A Houson, Luke Jaskowski, Chanelle Hunter, Benjamin M Larimer iD, Suzanne E Lapi

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Maxwell Ducharme und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Single-Domain Antibodies, Antineoplastic Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, University of Alabama at Birmingham.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the most aggressive forms of breast cancer involves the overexpression of human epidermal growth factor receptor 2 (HER2). HER2 is overexpressed in ∼25% of all breast cancers and is associated with increased proliferation, increased rates of metastasis, and poor prognosis. Treatment for HER2-positive breast cancer has vastly improved since the development of the monoclonal antibody trastuzumab (Herceptin) as well as other biological constructs. However, patients still commonly develop resistance, illustrating the need for newer therapies. Nanobodies have become an important focus for potential development as HER2-targeting imaging agents and therapeutics. Nanobodies have many favorable characteristics, including high stability in heat and nonphysiological pH, while maintaining their low-nanomolar affinity for their designed targets. Specifically, the 2Rs15d nanobody has been developed for targeting HER2 and has been evaluated as a diagnostic imaging agent for single-photon emission computed tomography (SPECT) and positron emission tomography (PET). While a construct of 2Rs15d with the positron emitter 68Ga is currently in phase I clinical trials, the only PET images acquired in preclinical or clinical research have been within 3 h postinjection. We evaluated our in-house produced 2Rs15d nanobody, conjugated with the chelator deferoxamine (DFO), and radiolabeled with 89Zr for PET imaging up to 72 h postinjection. [89Zr]Zr-DFO-2Rs15d demonstrated high stability in both phosphate-buffered saline (PBS) and human serum. Cell binding studies showed high binding and specificity for HER2, as well as prominent internalization. Our in vivo PET imaging confirmed high-quality visualization of HER2-positive tumors up to 72 h postinjection, whereas HER2-negative tumors were not visualized. Subsequent biodistribution studies quantitatively supported the significant HER2-positive tumor uptake compared to the negative control. Our studies fill an important gap in understanding the imaging and binding properties of the 2Rs15d nanobody at extended time points. As many therapeutic radioisotopes have single or multiday half-lives, this information will directly benefit the potential of the radiotherapy development of 2Rs15d for HER2-positive breast cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSingle-Domain AntibodiesAntineoplastic AgentsHumansFemaleTissue DistributionTrastuzumabPositron-Emission TomographyErb-b2 Receptor Tyrosine KinasesCell Line, TumorZirconium

Stichwörter der Autor:innen

HER2PETbreast cancerimagingnanobody

Substanzen

Single-Domain AntibodiesTrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsZirconium

Autor:innen und Institutionen

  • Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.
  • Department of Chemistry, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.

ORCID-Profile: Maxwell Ducharme, Lucinda Hall, Benjamin M Larimer

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • University of Alabama at Birmingham

Zitieren

APA

Ducharme, M., Hall, L., Eckenroad, W., Cingoranelli, S. J., Houson, H. A., Jaskowski, L., Hunter, C., Larimer, B. M., & Lapi, S. E. (2023). Evaluation of [ 89 Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00360

Vancouver

Ducharme M, Hall L, Eckenroad W, Cingoranelli SJ, Houson HA, Jaskowski L, et al. Evaluation of [ 89 Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00360

BibTeX
@article{Ducharme2023,
  author = {Ducharme, Maxwell and Hall, Lucinda and Eckenroad, Whitney and Cingoranelli, Shelbie J and Houson, Hailey A and Jaskowski, Luke and Hunter, Chanelle and Larimer, Benjamin M and Lapi, Suzanne E},
  title = {Evaluation of [ 89 Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00360}
}
Kostenlos starten →